These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32583196)

  • 1. Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases.
    Sherman SK; Schuitevoerder D; Chan CHF; Turaga KK
    Ann Surg Oncol; 2020 Dec; 27(13):5074-5083. PubMed ID: 32583196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.
    van der Heide DM; Turaga KK; Chan CHF; Sherman SK
    J Surg Res; 2021 Oct; 266():104-112. PubMed ID: 33989889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres.
    Grant M; Haydon A; Au L; Wilkins S; Oliva K; Segelov E; Antill Y; Carne P; Ranchod P; Polglase A; Farmer C; Chin M; Wale R; Simpson P; Bell S; Skinner S; McMurrick P; Shapiro J
    Int J Surg; 2018 Mar; 51():71-75. PubMed ID: 29367039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation between mismatch repair proteins status and clinicopathological characteristics in sporadic colorectal cancer patients].
    Xiao ZT; Zhang RX; Zhao Y; Peng JH; Lu SX; Zhang HZ; Ding PR; Wu XJ; Lu ZH; Li LR; Wan DS; Pan ZZ; Chen G
    Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(16):1248-1251. PubMed ID: 28441855
    [No Abstract]   [Full Text] [Related]  

  • 5. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
    World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
    Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
    Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
    PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology.
    Vivaldi C; Genovesi V; Ugolini C; Bernardini L; Casadei-Gardini A; Formica V; Salani F; Orsi G; Massa V; Cacciato-Insilla A; Caccese M; Cesario S; Andrikou K; Graziani J; Campani D; Vasile E; Fontanini G; Fornaro L; Masi G
    Oncology; 2024; 102(2):157-167. PubMed ID: 37699372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.
    Haraldsdottir S; Roth R; Pearlman R; Hampel H; Arnold CA; Frankel WL
    Fam Cancer; 2016 Apr; 15(2):253-60. PubMed ID: 26666765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma.
    González I; Goyal B; Xia MD; Pai RK; Ma C
    Hum Pathol; 2019 Mar; 85():18-26. PubMed ID: 30381262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
    JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer.
    He WZ; Hu WM; Wang F; Rong YM; Yang L; Xie QK; Yang YZ; Jiang C; Qiu HJ; Lu JB; Zhang B; Ding PR; Xia XJ; Shao JY; Xia LP
    J Natl Compr Canc Netw; 2019 Oct; 17(10):1174-1183. PubMed ID: 31590148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.
    Bielska AA; Chatila WK; Walch H; Schultz N; Stadler ZK; Shia J; Reidy-Lagunes D; Yaeger R
    J Natl Compr Canc Netw; 2021 Feb; 19(2):130-133. PubMed ID: 33545685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria.
    Sun CY; Chiang JM; Chen TC; Hung HY; You JF
    World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
    Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults.
    Shaikh T; Handorf EA; Meyer JE; Hall MJ; Esnaola NF
    JAMA Oncol; 2018 Feb; 4(2):e173580. PubMed ID: 29121143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer.
    Huang Q; Yu T; Li L; Zhang Q; Zhang S; Li B; Li X; Xiao W; Liu G
    Appl Immunohistochem Mol Morphol; 2023 Feb; 31(2):84-93. PubMed ID: 36409630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.